LIT-00814 / LittDD Medicines - LARVOL DELTA

Discovery of a potential therapeutic mechanism for selected tumors via targeting PI3K and DDR pathways simultaneously with a novel orally available small molecule (AACR 2025) - "The clinical phase I trials for LIT-00814 were initiated and the preliminary results hold promise to deliver beneficial therapy to selected cancer patients. In summary, we have discovered a novel orally available small molecule LIT-00814 targeting both mTOR and ATR with novel therapeutic mechanisms of action which could deliver beneficial therapy to selected cancer patients."

Oncology • AKT1 • AKT2

A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=81 | Enrolling by invitation | Sponsor: LittDD Medicines Ltd

Metastases • New P1 trial • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor